ArsenalBio

02/23/2022

For today’s , hear from Andrew C., a Senior Research Associate in Flow Cytometry, on what makes ArsenalBio such a great place to learn and grow.

02/22/2022

At ArsenalBio, we’re combining synthetic biology, engineering, machine learning and more to develop effective against . Learn more about our cutting-edge scientific approach here: https://bit.ly/3AD9rfB.

02/11/2022

Today, we honor the achievements of the women and girls in . Hear from our Arsenal about what inspires them to work in biotech.

02/04/2022

This , we honor cancer survivors, fighters and all the who are working to develop cures. CEO Ken Drazan, M.D., shares his personal family experience with cancer, and his reason to fight for a cancer-free world.

02/03/2022

Interested in learning more about the culture at ArsenalBio? Our company fact sheet includes information on our , , and more. Check it out here: https://bit.ly/3HqCZ2X

02/02/2022

This , we are honoring some of the brightest minds in by sharing the messages of Black who paved the way for the industry.

01/29/2022

Our CEO Ken Drazan, MD, was featured in Cell & Gene this morning! Hear Ken’s take on ArsenalBio’s pioneering approach and role in the future of engineering CAR-T in the Q&A by Erin Harris here:

ArsenalBio is taking different approaches to gene editing, target selection, cell circuit engineering, and computation to reimagine dosing, delivery, persistence, and affordability of cell therapy. The company is focused on integrating technologies such as CRISPR-based genome engineering, scaled....

01/27/2022

We’re and looking for talented and driven to join us on our mission to defeat cancers. View our open positions and apply here: https://bit.ly/3BjLTuU

01/26/2022

: News of our expanded collaboration with Bristol Myers Squibb was featured in FierceBiotech. Read the full article from Kyle LaHucik to learn more about the collaboration update during : https://bit.ly/3rKaGFX

Bristol Myers Squibb snagged two cell therapy deals for solid tumors and hematologic malignancies on Monday at the start of the J.P. Morgan Healthcare Conference. BMS is betting $3 billion in biobucks on Century Therapeutics' cell therapies and paying $70 million upfront for ArsenalBio's.

01/10/2022

Today, ArsenalBio CEO Ken Drazan will be presenting at the 40th Annual J.P. Morgan Healthcare Conference. Attending the virtual event? Tune into his presentation from 11:30 a.m. - 12:00 p.m. EST/8:30 - 9:00 a.m. PST. https://bwnews.pr/3JGzCq8

01/10/2022

Today, we announced that Bristol Myers Squibb has initiated a new program that expands its strategic collaboration with ArsenalBio. This partnership will allow us to discover and advance next generation therapies for the treatment of . Learn more here: https://bwnews.pr/3G8FC8K.

01/04/2022

Next week, our CEO Ken Drazan will be presenting at the JP Morgan Healthcare Conference. Learn more about the presentation, taking place on January 10th from 11:30 a.m. - 12:00 p.m. EST here: https://bwnews.pr/3JGzCq8

ArsenalBio to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference